数字人(835670) - 2023 Q4 - 年度财报

Financial Investments and Yields - The company purchased low-risk short-term financial products with its own funds, including a 3 million RMB product with an annual yield of 2.685%-3.395%[3], a 2 million RMB product with an annual yield of 6.277%[3], and a 5 million RMB product with an annual yield of 2.41%-2.43%[3] Government Subsidies - The company received government subsidies totaling 7,745,053.89 RMB, including 6,433,052.27 RMB from VAT refunds and 470,000 RMB from the 2023 Technology Innovation Guidance Plan[4] - Government subsidies received totaled 7,744,876.50, compared to 4,718,381.07 in the previous year[21] - Government subsidies are recognized when the conditions attached are met and the subsidies are receivable. Monetary subsidies are measured at the actual amount received, while non-monetary subsidies are measured at fair value or nominal amount (1 yuan) if fair value cannot be reliably determined[80] - The company and its subsidiaries classify government subsidies as either asset-related or income-related. Asset-related subsidies are deferred and recognized over the useful life of the related asset, while income-related subsidies are recognized as income when received[80] Asset and Financial Position - The company's total assets increased to 276,828,764.33 RMB from 272,061,845.68 RMB, with current assets rising to 203,997,015.45 RMB from 195,819,839.52 RMB[6] - The company's cash and cash equivalents increased by 23,498,324.32 RMB, reaching 141,342,846.25 RMB at the end of the year[7] - The company's statutory surplus reserve increased by 1,565,168.97 RMB to 17,190,862.67 RMB[13] - The company's undistributed profit at the end of the year was 74,512,389.43 RMB, up from 64,439,262.25 RMB at the beginning of the year[14] - The company's cash balance at the end of the year was 141,342,846.25, compared to 117,844,521.93 at the beginning of the year[74] - The company's total asset impairment loss was -341,086.66, compared to -394,756.53 in the previous year[67] - The company's long-term equity investment in subsidiaries remained unchanged at 17,000,000.00[76] - The company's total number of employees increased from 232 to 244, with notable increases in doctoral (2 to 3) and master's degree holders (11 to 12)[157] - The company's total share capital at the end of the year is 106,182,400.00 shares[132] - The company's total employee benefits for the year amount to RMB 38,404,721.48[130] - The company's total assets were RMB 276.83 million, with a slight increase of 0.03% compared to the performance forecast[180] - Shareholders' equity attributable to the parent company was RMB 251.94 million, a decrease of 0.10% compared to the performance forecast[180] Profit and Loss - The company's net profit attributable to the parent company's owners was 11,638,296.15 RMB, compared to a loss of 4,244,228.99 RMB in the previous year[14] - The company's consolidated profit for the year amounted to 11,467,535.90, with an income tax expense calculated at the statutory/applicable tax rate of 1,720,130.39[58] - The impact of different tax rates applied by subsidiaries resulted in a reduction of 379,259.19 in income tax expense[58] - The use of previously unrecognized deferred tax assets for deductible losses had a negative impact of 2,086,427.02 on income tax expense[58] - The impact of unrecognized deferred tax assets for deductible temporary differences or losses was 2,791,725.62[58] - Net profit attributable to shareholders was RMB 11.64 million, a decrease of 2.22% compared to the performance forecast[180] - Net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 7.85 million, a decrease of 3.25% compared to the performance forecast[180] - Basic earnings per share were RMB 0.11, with no variance compared to the performance forecast[180] - Weighted average return on equity (pre-deduction) was 4.73%, a decrease of 2.87% compared to the performance forecast[180] - Weighted average return on equity (post-deduction) was 3.19%, a decrease of 3.92% compared to the performance forecast[180] Revenue and Income - Rental income from buildings amounted to 695,502.02[19] - Revenue for the year was RMB 96.58 million, with no variance compared to the performance forecast[180] Accounts Receivable and Bad Debt Provisions - Accounts receivable within 1 year amounted to 27,693,823.71, an increase from 24,851,515.50 in the previous year[41] - Accounts receivable aged 1-2 years decreased significantly to 6,603,330.50 from 25,143,144.29 in the previous year[41] - The company's top five accounts receivable and contract assets at year-end include Wuhan Jinmao Engineering Technology Co., Ltd. with a balance of 9,482,407.20 CNY, accounting for 18.89% of the total[50] - The company's accounts receivable are classified into categories based on the method of bad debt provision. As of the end of the reporting period, the total accounts receivable were 48,925,152.15 yuan, with a bad debt provision of 16,787,354.12 yuan, representing a provision ratio of 34.31%[96] - The company's bad debt provision for significant individual accounts receivable increased from 4,607,672.40 yuan at the beginning of the year to 5,214,627.20 yuan at the end of the year, with a provision ratio of 100%[96][98] - The company recovered or reversed bad debt provisions totaling 4,607,672.40 yuan during the year, primarily due to sales returns from Chongqing Taimin Pharmaceutical Co., Ltd., a subsidiary of Sinopharm Holding[98] - Accounts receivable and contract assets year-end balance totaled 29,944,083.42, with a bad debt provision of 8,945,558.25, accounting for 59.56% of the total[99] - The year-end balance of contract assets was 1,343,874.86, with a bad debt provision of 121,209.39, resulting in a net book value of 1,222,665.47[99] - Other receivables year-end balance was 766,933.08, with a bad debt provision of 176,716.50, representing a provision ratio of 23.04%[102] - The year-end balance of other receivables classified by aging showed 487,826.16 within 1 year, 121,100.00 for 1-2 years, and 158,006.92 for over 3 years[105] - Bad debt provision for accounts receivable is RMB 16,787,354.12, with a book value of RMB 32,137,798.03[126] - Accounts receivable at the end of the reporting period amounted to 32.14 million yuan, accounting for 11.61% of total assets, with 43.27% of receivables aged over 1 year[146] - The company has implemented strict bad debt provision policies for long-aged receivables to accurately reflect asset conditions[146] Leases and Rental Expenses - Short-term lease expenses for the current period were 923,035.72, up from 818,007.32 in the previous year[39] - Interest expenses on lease liabilities for the current period were 112,475.87, down from 177,512.55 in the previous year[39] - Total cash outflows related to leases were 2,772,761.25, slightly lower than the previous year's 2,822,199.34[39] - For leases, the company and its subsidiaries recognize a right-of-use asset and lease liability at the commencement date, except for short-term leases and leases of low-value assets[82] - The company and its subsidiaries measure lease liabilities at the present value of lease payments not yet paid at the commencement date, using the lease's implicit interest rate or the incremental borrowing rate if the implicit rate cannot be determined[91] - The company and its subsidiaries re-measure lease liabilities when there are changes in fixed payments, residual value guarantees, indices or rates used to determine lease payments, or the assessment of purchase, renewal, or termination options[92] - Prepaid rent at the end of the year is RMB 124,076.27, compared to RMB 151,930.17 at the beginning of the year[129] Investments and Equity - The company holds significant influence over its associates, typically when it owns between 20% and 50% of the voting rights, unless there is clear evidence that it cannot participate in the decision-making process[44] - The company uses the equity method to account for investments in joint ventures and associates, adjusting the carrying amount of the investment if the initial cost differs from the share of the net assets' fair value[45] - When the company loses control over a subsidiary, it reclassifies the remaining equity using the equity method if it retains significant influence or joint control, otherwise, it applies the financial instruments accounting standard[46] - The year-end balance of other equity instrument investments remained unchanged at 5,000,000.00, with no additional investments or reductions during the year[110] Fixed Assets and Depreciation - The company's fixed assets, including buildings and equipment, are depreciated using the straight-line method with a residual value rate of 5% and an annual depreciation rate of 4.75% for buildings[51][52] - The year-end book value of fixed assets, including production equipment and office equipment, totaled 44,911,364.08, a slight increase from the previous year's 44,760,875.04[113] Cash Flow and Operating Activities - The company's net cash flow from operating activities was 32,050,406.98, a significant increase from the previous year's 6,984,399.12[74] - The company's cash and cash equivalents increased by 23,498,324.32 RMB, reaching 141,342,846.25 RMB at the end of the year[7] - The company defines cash and cash equivalents as cash on hand and deposits that are readily available for payment, as well as short-term investments with a maturity of no more than three months[56] Tax and Incentives - The company was re-certified as a high-tech enterprise in 2023, enjoying a reduced corporate income tax rate of 15% from 2023 to 2025[146] - The company's subsidiaries, Yichuang Medical and Shenzhen Yichuang, enjoy tax incentives for small and micro enterprises, including a 50% reduction in resource tax, urban maintenance and construction tax, property tax, urban land use tax, stamp tax, farmland occupation tax, education surcharge, and local education surcharge[94] - The company and its subsidiaries recognize deferred tax liabilities for all taxable temporary differences except those arising from initial recognition of goodwill or transactions that do not affect accounting profit or taxable income[81] R&D and Innovation - R&D expenditure for the current period is RMB 22,941,404.20, accounting for 23.75% of operating revenue[135] - The company's R&D expenditure decreased from RMB 25,224,420.88 in the previous period to RMB 22,941,404.20 in the current period[135] - The company has 7 R&D projects in 2023, with 6 focused on digital human projects and 1 on a subsidiary project in Shenzhen[164] - The "High-Definition Digital Human R&D and Industrialization Project" has been upgraded and is set to launch in 2024[164] - The "Digital Human Anatomy System" supports a comprehensive teaching platform covering pre-class, in-class, and post-class activities[164] - The "Digital Human Cloud Platform" has been accessed by over 58,000 students and 3,000 teachers[164] - The company's R&D team has accumulated extensive expertise in medical imaging, computer science, and clinical experience[167] - The company has established a comprehensive R&D management system to ensure project execution and quality[167] - The company's R&D expenses in 2023 were 22.94 million yuan, accounting for 23.75% of the operating revenue[164] - The company has a strong R&D team of over 100 members, covering expertise in computer technology and medicine, and possesses advanced digital anatomy technology platforms, including data acquisition, 3D modeling, and virtual reality technologies[197] - The company's "High-Definition Digital Human Virtual Anatomy Table System" and "Digital Human High-Definition Tomography 3D Printing Model" have been recognized as reaching international advanced and leading levels, respectively, by the Chinese Anatomical Society[197] - The company has launched the Digital Human Cloud Platform, addressing challenges in hybrid online and offline teaching, resource shortages, and uneven distribution of teaching resources, supporting new educational models like flipped classrooms[197] - The company has formed R&D teams with prestigious medical institutions such as the Army Medical University and Shandong University, integrating computer information technology with traditional medicine to develop innovative products[197] - The company holds 14 invention patents and 71 copyrights, with R&D investment exceeding 15% of operating revenue in recent years[199] - The company has won the Shandong Provincial Science and Technology Progress Third Prize in 2014 and the National Teaching Achievement Second Prize in 2018[199] Corporate Governance and Shareholding - The company's controlling shareholder and actual controller, Xu Yifa, directly holds 40.85% of the shares and controls a total of 41.71% of the company's shares[149] - The top ten shareholders collectively hold 55.08% of the company's shares, with no related party relationships among them[148] - Xu Yifa has served as the company's chairman since 2015 and continues to hold this position[149] - The company's board of directors approved the conclusion of some fundraising projects and the permanent replenishment of surplus funds on December 26, 2023[152] - The company's third board of supervisors approved the 2023 semi-annual report and summary on August 24, 2023[152] - The company's 2022 annual report, financial report, and profit distribution plan were approved at the 2022 annual shareholders' meeting on May 22, 2023[152] - The company revised several governance-related systems, including the "Articles of Association," "Board of Directors System," and "Supervisory Board System," during the reporting period[155] - The company's core employees' changes had no significant impact, and no specific measures were taken[158] - The company did not implement any equity incentive plans during the reporting period[160] - The company did not engage in any labor outsourcing during the reporting period[161] Market and Product Development - The company's main products include digital medical education products, life science popularization products, and interactive smart all-in-one machines[186] - The company has established a comprehensive R&D management system, including regulations on R&D projects, documentation, product naming, and review processes, ensuring the execution of R&D projects through stages such as initiation, implementation, and acceptance[192] - The company has collaborated with domestic medical universities, including Shandong University and Inner Mongolia Medical University, to develop high-precision digital human products, achieving high-definition human tomography data acquisition and processing, and has begun product development for clinical diagnostic assistance and sports anatomy[192] - The company's products are widely used in over 500 medical institutions and have been piloted in more than 30 countries overseas, with plans to expand further through promotional activities[197] - The company is focusing on strengthening its market presence in the medical education sector, optimizing product quality, and enhancing core competitiveness to effectively respond to market competition[192] - The company is expanding its overseas medical education market in line with the national "Belt and Road" strategy, aiming to capitalize on historical development opportunities[192] - The company has completed the design and implementation of life science museums in multiple medical universities, leveraging its data and technological advantages in digital medicine[199] - The company's interactive smart all-in-one machine, produced by its wholly-owned subsidiary Shenzhen Yichuang, features high-quality touch panels and is used in various scenarios including education, exhibitions, and video conferencing[199] - The company has established 12 provincial offices nationwide, covering over 60% of the market in medical colleges and universities, solidifying its leading position in the digital anatomy field[199] - The company's core team possesses extensive expertise in computer science and medicine, enabling efficient and precise services[199] - The company plans to expand its business scope from medical education to clinical medicine and public health[199] - The company's products and solutions are highly aligned with the high data professionalism requirements of medical universities[199] - The company has a mature sales network and a complete service closed-loop, with high brand recognition and reputation in the market[199] - The company's technological innovation and brand advantages provide a solid foundation for its high-quality development[199] Risk Management - The company faces risks related to intellectual property infringement and has implemented measures such as patent applications and employee confidentiality agreements[146] - Core technical personnel retention is a key risk, with the company implementing competitive compensation and performance evaluation systems to mitigate this[146] - The company is exposed to risks from changes in tax incentives for software and integrated circuit industries[146] - The company has strengthened credit management and collection systems to reduce accounts receivable risks[146] Fundraising and Projects - The company's "Digital Human Cloud Platform Construction Project" was completed and reached the intended usable state on December 21, 2023, with a remaining fund of 3,795,985.23 yuan (including interest and financial income) permanently replenishing working capital[154] - The company extended the construction period of the "High-Definition Digital Human R&D and Industrialization Construction Project" to December 31, 2024, without changing the funding purpose or investment scale[154] Events and Recognition - The company showcased new technologies and products at the 59th China Higher Education Expo in April[168] - The company hosted the first National Medical College Students' Morphology Reading and Human Anatomy Specimen Identification Skills Competition in May[168] - The company's "High-Definition Digital Human Virtual Anatomy System V1.0" was recognized as a 2023 Shandong Famous Brand[174] - The company's "High-Definition Digital